ZURICH, Aug 20 (Reuters) – Straumann, the world’s
largest maker of dental implants, could spend over $400 million
on buying cheaper rivals, signalling a desire to grab back
market share from low-cost competitors.
Faced with sluggish demand in its main market of Europe,
analysts and investors have urged Straumann and fellow premium
rival Nobel Biocare to develop cheaper brands to
compete in the fast-growing area of the market, which now
accounts for roughly 60 percent of volumes.
ZURICH, Aug 14 (Reuters) – Less than two weeks into the job,
Novartis AG’s new chairman is seeking to appease
investors by suggesting the Swiss drugmaker will review some of
its underperforming businesses in coming weeks.
Global drugmakers have stepped up the pace of restructuring,
as investors clamour for management to unlock value trapped
inside large firms.
ZURICH (Reuters) – European labor markets have reached a turning point, world No. 1 staffing firm Adecco (ADEN.VX: Quote, Profile, Research, Stock Buzz) said on Thursday, as it beat second-quarter profit expectations and saw its shares surge to a two-and-a-half year high.
Staffing firms are regarded by analysts as good indicators of future economic trends and Adecco’s more optimistic tone about the euro zone could add to expectations it will move out of recession later this year.
ZURICH (Reuters) – While a wave of stock market enthusiasm in the United States for biotech company flotations has yet to cross the Atlantic, venture capital appetite for promising European companies is returning.
Biotech is hot on Wall Street, with the Nasdaq sector index up 43 percent this year, listed U.S. stocks scaling all-time highs and roughly 23 biotech companies going public.
BASEL, Switzerland, July 25 (Reuters) – Swiss
pharmaceuticals firm Roche beat first-half profit
forecasts as strong sales of its mainstay cancer drugs and some
new treatments supported its view that it can withstand
competition from cheap, copycat drugmakers.
The results also stoked speculation the group might hike its
dividend, buy back shares and make more acquisitions as it looks
to diversify from its core expertise in cancer.
ZURICH, July 24 (Reuters) – Syngenta AG, the
world’s largest maker of crop chemicals, said on Wednesday it
expected underlying sales growth to pick up pace in the second
half of the year, after a cold, wet spring hit earnings in the
first six months.
Syngenta said it was confident high commodity prices would
encourage farmers to invest in crops in the second half of the
year, when demand is driven by South American farmers, and help
its 2013 sales surpass last year’s record of $14.2 billion.
ZURICH (Reuters) – The world’s biggest watchmaker, Swatch Group (UHR.VX: Quote, Profile, Research, Stock Buzz), said it expects faster sales growth and better margins in the second half as its Omega brand is growing again in China while demand for Harry Winston jewellery is buoyant.
In the first half of the year, there have been double-digit percentage falls in Swiss watch exports to China and Hong Kong, which absorbed a quarter of the timepieces that left Switzerland between January and June.
ZURICH, July 22 (Reuters) – Swiss drugmaker Roche
faces the prospect of hiring an outsider to replace its chairman
of 16 years after its most suitable board members turned down
The 117-year old company – the world’s largest maker of
cancer drugs – set itself an autumn deadline to find a successor
to Franz Humer, an influential, hands-on former Roche chief
executive who says he will not stand for re-election next year.
ZURICH, July 18 (Reuters) – Actelion, the Swiss
drugmaker which relies on sales of its treatment for a rare lung
disease, raised its full-year profit forecast on Thursday on
cost-savings and better-than-expected sales of its mainstay
Europe’s largest biotech company said it expected core
earnings to cross into the double-digit percentage range for
2013, up from a previous guidance of stable core earnings, after
cost savings kicked in quicker than expected.
ZURICH, July 17 (Reuters) – Novartis raised its
full-year outlook on Wednesday after generic competition to its
best-selling blood pressure pill was delayed, granting the Swiss
drugmaker a temporary reprieve from patent losses.
The Basel-based firm lost its patent rights on Diovan in the
United States last year and faced competition from a copycat
version of its monotherapy from Ranbaxy Laboratories.
But the lab has so far failed to get a green light for
production from U.S. regulators.